All News
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.
Read Article
Systemic Sclerosis Insights (9.13.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Increasing Incidence of Morphea
A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.
Read Article
Animal model shows Aggregatibacter actinomycetemcomitans periodontitis can trigger macrophage/caspase-11/inflammasome activation leading to paw swelling in mice anti-collagen antibody-induced arthritis (CAIA) model https://t.co/f41r28g5yr https://t.co/61NeXgfzmB
Dr. John Cush RheumNow ( View Tweet)
Norwegian Registry study compared risk of stroke in 2750 RA vs 158 879 w/o RA pts. 7.3 vs 5% (HR 1.36; 1.13, 1.62). RA pts with atrial fibrillation was also elevated (HR 1.25; 1.05, 1.5). RA pts less likely to Rx w/ oral anticoagulants (adj OR 0.88) than non-RA… https://t.co/uprHZbsqkR https://t.co/edjoN2vzc0
Dr. John Cush RheumNow ( View Tweet)
REAL-HLH, a retrospective study of emapalumab (anti-IFNg) was effective in Rheum (15 pts) w/ hemophagocytic lymphohistiocytosis (10 w/ Still's disease, 60% in ICU w/ refractory Dz). EMA normalized CXCL9, ANC, decr steroids & had 12 mo survival=87% https://t.co/MgYul9rCqV https://t.co/pDpriVvAdg
Dr. John Cush RheumNow ( View Tweet)
CAR-T Like Effects with Bispecific Teclistamab
A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody… https://t.co/FO42QaJaFn https://t.co/5LouAzYeOv
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/yIBlyNZacB https://t.co/dempwjX5XO
Dr. John Cush RheumNow ( View Tweet)
Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/YgtujQjNqI https://t.co/9uazZLuoRb
Dr. John Cush RheumNow ( View Tweet)
JAMA: RCT in 101 chronic low back pain pts showed a single nondeceptive placebo injection reduced LBP intensity for 1 month https://t.co/TmAIHswwli https://t.co/MwdE7MhQKI
Dr. John Cush RheumNow ( View Tweet)
Moving Forward on RA Prevention Trials
Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess… https://t.co/ppmWa27tgd https://t.co/lQEtBNRZRm
Dr. John Cush RheumNow ( View Tweet)
Conservative Treatment of Acute Vertebral Fractures
A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term… https://t.co/uqQAoypdiV https://t.co/HNgKtzMs03
Dr. John Cush RheumNow ( View Tweet)
ACR Speaks Against Repeated Cuts to Medicare Reimbursements
The ACR has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheums and rheum interprofessional team members’ ability to… https://t.co/cIjJwOWA5Z https://t.co/sPLZFUxywl
Dr. John Cush RheumNow ( View Tweet)
Study of 65 myositis pts w/ PM/Scl Abs found ILD as a dominant feature, esp. if double pos. w/ myositis-specific Abs (MSAs 52%). PM/Scl+ more likely women (90 vs 68%), w/ sclerodactyly (16 vs 0%). Double ++ had more ILD (91%) & mortality (21% vs 0) https://t.co/grz7NW410N https://t.co/pdDilBabdf
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush RheumNow ( View Tweet)
Consensus Guidelines on Pediatric Methotrexate Use
MTX is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects:
-indications and contraindications… https://t.co/6JtIMGOAhq https://t.co/OZJLqAyOnF
Dr. John Cush RheumNow ( View Tweet)
UK Biobank study of 34209 pts w/ Abdominal MRIs found a dose response assoc. between visceral & subcutaneous fat and chronic MSK pain, moreso in women. Is adiposity causal or casual in the pathogenesis of chronic pain? https://t.co/w4ziJf7FQD https://t.co/SyUfCPOnHX
Dr. John Cush RheumNow ( View Tweet)
Wales registry of primary Unilateral knee replacements (UKRs) for #OA (n 106,206) found no outcome differences based on level of training (15 yr UKR failure rates equal for Trainees/16.4% vs Consultants/17.13% https://t.co/uIo4Sv8Lfu https://t.co/LEMrf3vHaR
Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.
https://t.co/xP65pw5zCw https://t.co/T0nBO3HMIP
Dr. John Cush RheumNow ( View Tweet)
A low risk of Candida infections with ixekizumab (IXE); integrated analysis of 25; Candida infx rates - PsO:1.9/100 PY (N 6892); PsA 2.0/100 PY (N 1401); axSpA 1.2/100PY (N 932). Most occured only once, were mild/moderate & were oral or genital Candida https://t.co/ZkkPoSzPMW https://t.co/VysnaQ8rpi
Dr. John Cush RheumNow ( View Tweet)